Aurora Cannabis Inc. (ACB)
| Market Cap | 176.81M |
| Revenue (ttm) | 229.67M |
| Net Income (ttm) | -97.41M |
| Shares Out | 61.94M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,281,751 |
| Open | 2.750 |
| Previous Close | 2.760 |
| Day's Range | 2.750 - 2.855 |
| 52-Week Range | 2.730 - 6.665 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 6.15 (+117.31%) |
| Earnings Date | Jun 11, 2026 |
About ACB
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient ... [Read more]
Analyst Forecast
According to 6 analysts, the average rating for ACB stock is "Buy." The 12-month stock price target is $6.15, which is an increase of 117.31% from the latest price.
News
Aurora Cannabis Reports Strong Q4 and Full-Year Results, Stock Ticker: ACB
Aurora Cannabis Reports Strong Q4 and Full-Year Results, Stock Ticker: ACB
Aurora Cannabis (ACB) Reports Q4 FY26 Results with Mixed Outlook
Aurora Cannabis (ACB) Reports Q4 FY26 Results with Mixed Outlook
Aurora Cannabis Q4 Earnings Call Highlights
Aurora Cannabis NASDAQ: ACB reported a stronger fiscal 2026 performance than it had forecast, driven by growth in global medical cannabis, while warning that fiscal 2027 will be a “reset year” as Cana...
Aurora Cannabis (ACB) Reports Strong Q4 Earnings with Revenue Growth
Aurora Cannabis (ACB) Reports Strong Q4 Earnings with Revenue Growth
Aurora Cannabis (ACB) Reports Q4 Financial Results and Growth Strategy
Aurora Cannabis (ACB) Reports Q4 Financial Results and Growth Strategy
Aurora Cannabis Earnings Call Transcript: Q4 2026
Net revenue and adjusted EBITDA exceeded guidance in FY26, driven by global medical cannabis growth and operational efficiencies. FY27 is expected to see lower revenue due to Canadian reimbursement changes, but international expansion and acquisitions like Safari Flower support long-term growth.
Aurora Cannabis Annual report: Q4 2026
Aurora Cannabis has published its Q4 2026 annual report on June 11, 2026.
Aurora Cannabis Registration statement: Q4 2026
Aurora Cannabis filed a registration statement on June 11, 2026, providing details about a securities offering with the SEC.
Aurora Cannabis Registration statement: Q4 2026
Aurora Cannabis filed a registration statement on June 11, 2026, providing details about a securities offering with the SEC.
Aurora Cannabis Earnings release: Q4 2026
Aurora Cannabis released its Q4 2026 earnings on June 11, 2026, summarizing the period's financial results.
Aurora Cannabis Slides: Q4 2026
Aurora Cannabis has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 11, 2026.
Aurora Cannabis Earnings release: Q4 2026
Aurora Cannabis released its Q4 2026 earnings on June 11, 2026, summarizing the period's financial results.
Aurora Cannabis reports Q4 revenue C$84.8M vs. C$76.8M last year
Reports Q4 adjusted EBITDA $9.2M vs. $14.1M last year. “During FY26, we exceeded our projection for global medical cannabis net revenue1 led by double-digit growth in Europe and delivered on…
Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹
NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth Delivers Record Annual Adjusted EBITDA 1 of $53.8 million, representing 32%...
Upcoming Earnings Reports: Aurora Cannabis (ACB) and More
Upcoming Earnings Reports: Aurora Cannabis (ACB) and More
Aurora Cannabis (ACB) Expands Support for Canadian Veterans with New Donations
Aurora Cannabis (ACB) Expands Support for Canadian Veterans with New Donations
Aurora Deepens its Impact for Veterans Across Canada
NASDAQ | TSX: ACB From global leadership to local impact, Aurora continues to support Veteran-focused programs across Canada, addressing food security, mental health, and community engagement EDMONTON...
Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information
NASDAQ | TSX: ACB EDMONTON, AB, May 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, annou...
Top Canadian Marijuana Stock Choices For Better Investing In 2026
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet the...
Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science
NASDAQ | TSX: ACB Canadian grant protects Aurora‑developed genetics bred through the company's advanced research and breeding program EDMONTON, AB, May 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NA...
Top Canadian Cannabis Penny Stocks to Watch This Month
The cannabis sector continues to attract investors seeking growth opportunities in 2026. Marijuana penny stocks remain volatile. However, they also offer strong upside potential when market momentum i...
Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets
NASDAQ | TSX: ACB Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support g...
'GIANT STEP FORWARD': Reclassification of medical cannabis lauded
Trulieve founder and CEO Kim Rivers discusses the impact of Trump's administration reclassifying state-licensed medical cannabis from Schedule 1 to Schedule 3 on 'Varney & Co.' 00:00 Introduction & Re...
'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana
The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday. FDA-approved and state-licensed medical marijuana was rescheduled from a Schedule I drug to the less stric...
The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off
Marijuana stocks sold off Thursday, after acting U.S. Attorney General Todd Blanche signed an order rescheduling Food and Drug Administration-approved and state-licensed medical cannabis products as a...